Amanda Tu

The GSB Impact Fund is an evergreen fund that invests in early-stage for-profit ventures seeking both financial and social and environmental returns.

The GSB Impact Fund is an evergreen fund that invests in early-stage for-profit ventures seeking both financial and social and environmental returns.

At Oliver Wyman, a Marsh business, we bring deep industry insight, bold innovation, and a collaborative approach that cuts through complexity to help organizations navigate their most defining transformative moments. As a business of Marsh, we work alongside the world’s leading experts across risk, reinsurance and capital, people and investments, and management consulting. Together with Marsh Risk, Guy Carpenter, and Mercer, we help organizations build resilience and competitive advantages from every angle. With annual revenue over $24 billion and more than 90,000 colleagues in 130 countries, Marsh helps build the confidence to thrive through the power of perspective

Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology & biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is built of Life Science Founders with experience in raising capital, scaling teams, running labs, partnering with Pharma, & the many fires that consist of operating an early stage company. Founders, we’d love to partner with you along the journey & help translate daunting ideas into world shaping innovations - here’s to a better brighter future for patients! SAB: Composed of Bioengineering PhDs turned Founders, our Scientific Advisory Board provides deep technical expertise & fluency across a wide variety of Life Science sub-domains from platforms for “Novel Applications” (Therapeutics/Diagnostics) to “Bio-Economy Infrastructure” (Tools/Services/Manufacturing). Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large Payors.

Stanford Medicine X is the worlds leading patient-centered program on emerging technology and medicine. Thought leaders and innovators in patient-centered innovation and digital health join us year-round on campus at Stanford University and at our program events around the globe to learn about new ways of creating wellness and improving health care in partnership with all healthcare stakeholders.

Were a hands-on, collaborative, and entrepreneur friendly early stage venture capital firm. We focus on equity investments in companies with dramatic growth potential, primarily in technology and highly-scalable services businesses.